跳至主要内容
临床试验/NCT05645055
NCT05645055招募中不适用

The Clinical Outcomes of Patients With Stricturing Crohn's Diseases Received Biologics: a Prospective, Observative Study

Jinling Hospital, China1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
clinical remission rate at 1 year

研究概览

简要总结

Recent researches have reported that biologics might be also effective for stricturing CD. However, the data were largely retrospective. Prospective studied are needed for evaluate the efficacy of biologics for stricturing Crohn's diseases.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with stricturing Crohn's diseases
  • no surgical indication
  • patients with asymptomatic penetrating diseases
  • written consent acquired

排除标准

  • patients with surgical indication
  • patients with symptomatic penetrating diseases
  • contraindication of biologics
  • anticipating other trial

结局指标

主要结局

clinical remission rate at 1 year

时间窗: clinical remission rate at 1 year

clinical remission rate at 1 year (CDAI less than 150)

次要结局

  • quality of life of patients assessed by Short form 12(at 2, 4, 6 , 8 months and at 1, 2, 3, 4 and 5 year)
  • surgical recurrence rate at 1 and 5 year(at 1 and 5 year)
  • quality of life of patients assessed by IBDQ(at 2, 4, 6 , 8 months and at 1, 2, 3, 4 and 5 year)
  • score of obstructive(at 2, 4, 6 , 8 months and at 1, 2, 3, 4 and 5 year)
  • endoscopic recurrence rate at 1 and 5 year(at 1 and 5 year)
  • clinical remission rate at 5 year(clinical remission rate at 5 year)

研究者

发起方
Jinling Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhu Weiming

Senior Doctor, Principal Investigator, Clinical Professor

Jinling Hospital, China

研究点 (1)

Loading locations...

相似试验